Business
VAXIL’s Annual and Special Shareholders Meeting
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), announces that at the Company's Annual and Special General Meeting, held virtually, on March 31, 2025, all resolutions were duly passed by shareholders. ABOUT VAXIL Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product Im
About this update from Vaxil Bio Ltd.
[{"type":"image","alt":"Vaxil Bio Ltd.","displaySize":"","headline":null,"caption":"Vaxil Bio Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/4a6f0535137a79360b3f4e9ec1a21f3a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bK1nCd_d4yOCBGItsFwqyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4a6f0535137a79360b3f4e9ec1a21f3a","width":300,"height":138}},"lazy":false},{"type":"text","content":"Not for distribution by US newswire or in United States","length":55,"tagName":"p"},{"type":"text","content":"NESS-ZIONA, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), announces that at the Company's Annual and Special General Meeting, held virtually, on March 31, 2025, all resolutions were duly passed by shareholders.","length":273,"tagName":"p"},{"type":"text","content":"ABOUT VAXIL ","length":11,"tagName":"p"},{"type":"text","content":"Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The Company is presently evaluating whether to continue to develop ImMucin™ or to pursue other business, which may or may not be in the biotechnology industry, in order to enhance shareholder value.","length":487,"tagName":"p"},{"type":"text","content":"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.","length":204,"tagName":"p"},{"type":"text","content":"Disclaimer: The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to...